Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

President-elect Donald Trump has asserted that, due to national security interests, he intends to acquire Greenland and ...

The Korean unit of Danish health care giant Novo Nordisk signed a memorandum of understanding with Seoul National University ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on January 13 and set a price target of ...

which Novo Nordisk falls in, has lost 4.2%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...